Disruption of glandular architecture associates with poor clinical outcome in high-grade colorectal cancer (CRC). Phosphatase and tensin homolog deleted on chromosome ten (PTEN) regulates morphogenic growth of benign MDCK (Madin Darby Canine Kidney) cells through effects on the Rho-like GTPase cdc42 (cell division cycle 42). This study investigates PTEN-dependent morphogenesis in a CRC model. Stable short hairpin RNA knockdown of PTEN in Caco-2 cells influenced expression or localization of cdc42 guanine nucleotide exchange factors and inhibited cdc42 activation. Parental Caco-2 cells formed regular hollow gland-like structures (glands) with a single central lumen, in three-dimensional (3D) cultures. Conversely, PTEN-deficient Caco-2 ShPTEN cells formed irregular glands with multiple abnormal lumens as well as intra-and/or intercellular vacuoles evocative of the high-grade CRC phenotype. Effects of targeted treatment were investigated. Phosphatidinylinositol 3-kinase (PI3K) modulating treatment did not affect gland morphogenesis but did influence gland number, gland size and/or cell size within glands. As PTEN may be regulated by the nuclear receptor peroxisome proliferator-activated receptor-g (PPARg), cultures were treated with the PPARg ligand rosiglitazone. This treatment enhanced PTEN expression, cdc42 activation and rescued dysmorphogenesis by restoring single lumen formation in Caco-2 ShPTEN glands. Rosiglitazone effects on cdc42 activation and Caco-2 ShPTEN gland development were attenuated by cotreatment with GW9662, a PPARg antagonist. Taken together, these studies show PTEN-cdc42 regulation of lumen formation in a 3D model of human CRC glandular morphogenesis. Treatment by the PPARg ligand rosiglitazone, but not PI3K modulators, rescued colorectal glandular dysmorphogenesis of PTEN deficiency.
INTRODUCTION
The tumor suppressor PTEN (phosphatase and tensin homolog deleted on chromosome ten) regulates 3D morphogenesis in a benign MDCK (Madin Darby Canine Kidney) model of polycystic kidney disease, through effects on the Rho GTPase cdc42 (cell division cycle 42).
1 Cdc42 partitions between cytosol and cell membrane fractions 2 and can be activated for distinct functions at separate subcellular loci, by specific guanine nucleotide exchange factors (GEFs). 3 In a small interfering RNA (siRNA) screen of 70 GEFs, the cdc42 GEFs Tuba and intersectin 2 (ITSN2) were shown to have a key role in 3D MDCK epithelial morphogenesis. 4 Tuba promotes apical enrichment and activation of cdc42, 4 while ITSN2 colocalizes with cdc42 close to the apical membrane. 5 Once activated, cdc42 binds to a protein complex containing partitioning defective polarity proteins 3, 6 and atypical protein kinase C (aPKC) [6] [7] [8] to regulate polarized growth. 9 The cdc42/Par/ aPKC polarity complex promotes GSK3b phosphorylation at serine 9 (Ser9) 10 and triggers actomyosin flow. 11 Suppression of cdc42 induces spindle misorientation in adherent cells, 12 disorganized apical membrane positioning and formation of multiple irregular lumens or inter-or intracellular vacuoles in 3D epithelial cultures. 13, 14 PTEN regulates 3D epithelial morphogenesis by recruitment and activation of cdc42 at the apical membrane 1 but associations between PTEN, 'morphogenic' GEFs and cdc42 activation remain unclear.
PTEN mutation or deficiency distorts glandular architecture during early neoplastic progression 15 and associates with highly dysmorphic colorectal cancer (CRC) phenotypes. 16 However, effective treatment of cancer dysmorphogenesis is lacking. While PTENdeficient human CRC 17 may represent a suitable target for phosphoinositide 3-kinase (PI3K) inhibitory therapy, 18, 19 PTEN also has crucial phosphatase-independent tumor suppressor functions. [20] [21] [22] PTEN expression may be upregulated by peroxisome proliferatoractivated receptor-g (PPARg), through PPAR responsive elements within the PTEN promoter. 23, 24 This study has used wild-type (wt) Caco-2 CRC cells and a subclone rendered PTEN deficient by stable transfection with short hairpin RNA (Caco-2 ShPTEN cells), to investigate PTEN-dependent morphogenic signaling and test effects of targeted treatment. This system models the incomplete post-transcriptional suppression of PTEN by targeting miRNAs that characterizes human sporadic CRC. 25 Here we show that PTEN deficiency in neoplastic colorectal epithelium is associated with impairment of cdc42-dependent morphogenic signaling. Stable knockdown of PTEN inhibited expression and membrane localization of Tuba and promoted cytoplasmic retention of ITSN2. While PI3K activating treatment enhanced membrane recruitment of Vav2 in Caco-2 ShPTEN cells, ITSN2 and Tuba were unaffected. In 3D cultures, PTEN-deficient (Caco-2 ShPTEN) cells formed gland-like structures (glands) with irregular apical membrane positioning with respect to gland centers, multiple abnormal lumens and/or inter-or intracellular vacuoles. Transfection of cdc42 rescued Caco-2 ShPTEN gland morphogenesis. Pharmacological modulation of phosphatidinylinositol 3-kinase (PI3K) signaling had limited effects on cdc42 activity, influenced gland number and size as well as cell size within glands, but did not affect the multilumen/vacuolar phenotype of PTEN-deficient glands. Conversely, treatment of cells with the PPARg ligand rosiglitazone 26 enhanced PTEN expression, increased cdc42 activity and rescued Caco-2 ShPTEN gland morphogenesis.
Taken together, these data indicate that PTEN has a key role in spatiotemporal coordination of specific GEFs and cdc42, crucial for colorectal glandular morphogenesis. As PPARg-targeted treatment, but not PI3K modulators, rescues defective gland formation, PPARg ligands may represent attractive candidates for further preclinical development as therapy for CRC glandular dysmorphogenesis.
RESULTS

PTEN deficiency impairs cdc42 signaling
To investigate the effects of PTEN deletion or deficiency on cdc42 activity, we used isogenic PTEN-expressing parental colorectal cells vs null or deficient subclones. PTEN À / À HCT116 cells were previously generated from parental PTEN þ / þ HCT116 cells using a high-efficiency promoterless PTEN targeting vector. 27 We generated a PTEN-deficient Caco-2 subclone by stable transfection of Caco-2 cells with PTEN short hairpin RNA, 28 then selected, characterized and pooled PTEN-deficient clones to generate the Caco-2 ShPTEN cell line (Supplementary Figure S1) . Full activation of Akt requires phosphorylation on threonine 308 (Thr308) and serine 473 (Ser473) residues 29 and we therefore assessed phosphorylation at both sites. Parental PTEN þ / þ HCT116 and Caco-2 cells had lower Akt Thr308 and Ser473 phosphorylation (pAkt) than PTEN À / À HCT116 or Caco-2 ShPTEN cells (Figure 1a) , consistent with PTEN suppression of phosphatidylinositol (PtdIns) (3,4,5) P 3 and PI3K-Akt signaling. 30 Cdc42 activation was greater in the parental lines than in PTEN-null or -deficient subclones (Figures 1a-c) . Once activated, cdc42 forms a polarity complex with Par6 and aPKC that promotes GSK3b Ser9 phosphorylation. 10 GSK3b phosphorylation (pGSK3b) was greater in the parental PTEN þ / þ HCT116 and Caco-2 lines than in PTEN-null or -deficient subclones, consistent with the greater cdc42 activity in those cells (Figure 1a ). Cdc42 may be activated by wounding 31 and PTEN þ / þ HCT116 cells maintained consistently higher cdc42 activity and pGSK3b after monolayer wounding than PTEN À / À HCT116 cells (Figure 1d) . To investigate the cell specificity of PTEN regulation of cdc42, we conducted PTEN siRNA knockdown studies in A-549 human lung and MDA-MB 235S human mammary epithelial cells. PTEN siRNA transfection suppressed cdc42 activity versus nontargeting siRNA in these cells (Supplementary Figure S2) . Hence, PTEN may enhance cdc42 activity in various epithelial cell types despite its capacity for suppression of PtdIns (3,4,5)P 3 .
Effects of PI3K modulating treatment on cdc42 signaling To further investigate the role of PI3K-Akt signaling on cdc42 activity, we assessed effects of PI3K activators or inhibitors. Background pAkt was greater in PTEN-deficient PTEN À / À HCT116 cells or Caco-2 ShPTEN than the parental cells and was modulated by epidermal growth factor (EGF) or wortmannin treatment. The pretreatment cdc42 activation state was greater in PTEN-expressing cells. Taking this factor into account, quantitative effects of EGF on cdc42 activation appeared similar in the presence or absence of PTEN (Figures 2a-c) . Treatment by different PI3K-Akt activators or inhibitors (insulin-like growth factor (IGF) vs LY294002) produced broadly similar results (Figure 2d ). These data indicate that cdc42 may be activated by PTEN and PI3K-Akt signaling. pGSK3b Ser9 was also enhanced or suppressed by EGF/IGF or wortmannin/LY294002 treatment, respectively, in tandem with effects on cdc42 activation (Figures  2a-d) .
PTEN-negative regulation of PtdIns (3,4,5)P 3 32 impedes plasma membrane recruitment of the cdc42 GEF Vav2. 33 To investigate the role of PTEN and PI3K signaling in membrane recruitment of 'morphogenic' vs'non-morphogenic' GEFs, represented by Tuba and ITSN2 vs Vav2, respectively, 4 we conducted cell fractionation experiments. Membrane and cytosolic localization of GEFs were assessed in Caco-2 and Caco- Caco-2 glands predominantly comprised regular hollow spheres with a single central lumen surrounded by an epithelial monolayer of uniform cells. Conversely, substantive dysmorphogenesis was observed in Caco-2 ShPTEN glands. These contained multiple abnormal lumens, inter-and/or intracellular vacuoles, showed irregular orientation of the aPKC apical membrane marker in relation to gland centers and were formed from large-sized epithelial cells (Figures 3a and b) . We investigated the role of cdc42 in 3D morphogenesis by transfection studies. As anticipated, transient transfection of Caco-2 or Caco-2 ShPTEN cells in monolayer culture with wt or constitutively active (CA) cdc42 constructs upregulated cdc42 activity (Figure 3c ). We then stably transfected Caco-2 ShPTEN cells with GFP-labeled cdc42 constructs, for 3D culture. Transfection of wt cdc42 restored formation of a single central lumen in 470% Caco-2 ShPTEN glands vs 43% and 37% for empty vector (EV) or dominant-negative (DN) cdc42 transfections, respectively (Figures 3d and e). Orientation of aPKC or E-cadherin markers in relation to cell apices or basolateral regions was unaffected by cdc42 transfections (Figure 3d ). As the effects of cdc42 knockdown upon 3D Caco-2 morphogenesis were shown in a previous study, 13 those experiments were not repeated. Taken together, these findings show a mechanistic link between PTEN, cdc42 and 3D morphogenesis in a CRC model system.
Effects of PI3K modulating treatment on 3D epithelial morphogenesis The structural morphology of CRC has major prognostic significance 34 and its molecular regulatory framework could represent a novel target for therapy. Hence, we assessed the effects of PI3K activating or inhibitory treatment on 3D morphogenesis. Caco-2 and Caco-2 ShPTEN cells were incubated with EGF or wortmannin. Treatment was applied either from the first day of 3D culture or after 10 days of culture. Neither regimen influenced Caco-2 or Caco-2 ShPTEN gland lumen formation or orientation of the apical aPKC marker with respect to gland centers (Figure 4a and b) . However, these PI3K activating or suppressive treatments enhanced or suppressed epithelial cell size within Caco-2 and Caco-2 ShPTEN glands (Supplementary Figure  S4a) . We then tested a PI3K inhibitor with longer half-life (PI-103) vs EGF or medium-only control. Treatment was administered from the first day of culture and renewed every 48 h. PI-103 treatment reduced the total number of Caco-2 and Caco-2 ShPTEN glands formed (to 29 Effects of rosiglitazone treatment on PTEN expression, cdc42 activation and 3D epithelial morphogenesis PTEN contains two PPARg responsive elements within its promoter region. 23 In this study, treatment with the PPARg ligand rosiglitazone (10 mM (Figure 5a ). The study dose was optimized in dose-response studies (Supplementary Figure S5a) . Rosiglitazone treatment also enhanced cdc42 activation in both Caco-2 and Caco-2 ShPTEN cells, although these effects were inhibited by cotreatment with GW9662, a specific PPARg antagonist 26 ( Figure 5b) . Rosiglitazone treatment had a dramatic effect on lumen formation in Caco-2 ShPTEN glands, restoring a single central lumen in 60% Caco-2 ShPTEN glands vs 33% for VO-treated controls (Figure 5c ). Rosiglitazone rescue of lumen formation in Caco-2 ShPTEN glands was blocked by cotreatment with GW9662 (Figure 5d ). In addition to the effects on morphogenesis, rosiglitazone treatment also suppressed the size of the developing Caco-2 ShPTEN glands by 12 days of culture vs control (Supplementary Figure S5b) .
DISCUSSION
In this study, PTEN expressing PTEN þ / þ HCT116 and Caco-2 parental cells had low Akt phosphorylation at both Thr308 and Ser473 sites, but greater cdc42 activity and greater GSK3b Ser9 phosphorylation than PTEN-null or -deficient subclones, in resting and scratch-activated conditions. PTEN expression invoked higher cdc42 activity than PTEN knockdown in various cell types. Previous studies have shown seemingly paradoxical effects of PTEN on cdc42 signaling. PTEN dephosphorylates PtdIns (3,4,5) P 3 32 that promotes plasma membrane recruitment of the cdc42-activating GEF Vav2 33 and inhibits GTP-bound cdc42 in murine fibroblasts. 35 Conversely, PTEN promotes membrane recruitment and activation of cdc42 during 3D MDCK epithelial morphogenesis, and PTEN SiRNA knockdown suppresses cdc42 activity in MDCK epithelial monolayers. 1 Sophisticated technologies have helped to resolve this paradox and brought a new conceptual framework for GTPase function. As opposed to traditional concepts of a single polarization event governed by total intracellular GTPase activity, it is now recognized that spatially restricted GTPase activity is regulated by specific GEFs for different functions, during cellular and multicellular morphogenesis. GSK3b Ser9 phosphorylation can be enhanced by the cdc42/ Par/aPKC polarity complex 10 as well as Akt. 36 Our findings suggest dominance of the former mechanism in our model system. Although we cannot exclude some cell specificity in these effects, our findings accord with previous studies that identified a cooperative PTEN/GSK3b feedback loop. 37 GSK3b phosphorylates and destabilizes PTEN. 37 Conversely, pharmacological inhibition of GSK3b function by phosphorylation at Ser9 38 may enhance PTEN expression. 39, 40 Hence, high GSK3b Ser9 phosphorylation may permit high PTEN expression. Furthermore, the well-characterized GSK3b inhibitor lithium chloride, 41 enhances PTEN expression 40 and may promote GSK3b Ser9 phosphorylation by pAktindependent mechanisms. 42, 43 Taken together, these studies are consistent with PTEN-associated, pAkt-independent mechanisms of GSK3b Ser9 phosphorylation, in accord with our findings. To explore PTEN-targeted therapy, we assessed effects of PI3K activation by growth factors (EGF or IGF) 44 or inhibition by wortmannin or LY294002 treatment. 29 EGF/IGF vs wortmannin/ LY294002 treatment, respectively, enhanced or suppressed cdc42 activation and pGSK3b levels. Quantitative differences between parental PTEN þ / þ HCT116 and Caco-2 cells vs PTEN-deficient subclones suggest cdc42 activation by both PI3K signaling and PTEN expression. Growth factors and other upstream signals recruit cdc42 GEFs to convert the GDP-bound form to active GTPcdc42. 45 Specific GEFs can coordinate spatiotemporal cdc42 activity during a morphogenic response 3 by targeting the GTPase within macromolecular complexes, to key cellular subdomains. 46 Rho-family GEFs have pleckstrin-(PH) 46 and Dblhomology (DH) domains 47 that mediate signal-dependent membrane recruitment and GTPase activation. For example, binding of the Vav2 PH domain to membrane PtdIns (3,4,5) P 3 promotes PH-DH domain interactions 48 that catalyze guanine nucleotide exchange and GTPase activation. 49 ITSN2 and Tuba are dependent upon their DH domain function for cdc42 activation, 4,50 but they differ from other Dbl family Rho-GTPase, in terms of their PH-DH domain interactions. The ITSN2 PH domain does not directly contact cdc42-substrate complexes, nor influence intrinsic DH domain catalytic activity and its activation of cdc42 is PtdIns (3,4,5) P 3 -and PI3K-independent. 51 Tuba does not possess a PH domain 52 but instead contains an evolutionarily conserved Bin/amphiphysin/Rvs (BAR) domain 52 that binds to phosphatidylserine within the plasma membrane lipid bilayer. 53, 54 To investigate co-dependencies between PTEN, PI3K signaling and subcellular localization of 'morphogenic' and 'non-morphogenic' GEFs, we conducted cell treatment and fractionation studies. We found quantitative, localization and phosphatidylinositide-affinity differences between specific cdc42 GEFs that could provide a rationale for our finding of dual activation of cdc42 by both PTEN and PI3K signaling. Greater membrane and cytosolic accumulation of Tuba and Vav2 associated with PTEN expression could thus enhance total cdc42 activity in Caco-2 vs Caco-2 ShPTEN cells. Conversely, greater cytosolic retention of ITSN2 in Caco-2 ShPTEN cells could impede ITSN2 colocalization with and activation of cdc42 at the plasma membrane. PI3K activating treatment enhanced membrane recruitment of Vav2 in Caco-2 ShPTEN cells, but had no discernible effects on ITSN2 or Tuba. Hence, this study is consistent with PTEN dual regulation of cdc42 by phosphatase-dependent and -independent effects on expression and membrane localization of specific cdc42 GEFs.
Elucidation of regulatory mechanisms of glandular dysmorphogenesis in high-grade CRC has been hampered by the scarcity of suitable model systems. Caco-2 cells retain the capacity for 3D cell-cell interactions implicated in glandular architecture and provide a suitable CRC morphogenesis model. 55 In this study, we found that Caco-2 cells formed regular gland-like structures with a single central lumen, surrounded by a uniform monolayer of polarized epithelial cells in 3D organotypic culture. Cell-cell adhesion was maintained through adheren junctions identified by E-cadherin expression. Furthermore, the aPKC apical membrane marker 56 formed a homogeneous continuous interface with the gland lumen, in agreement with previous reports. 13, 55 We found that PTEN knockdown provoked a dramatic change in the organization of these gland-like structures. Caco-2 ShPTEN glands formed multiple lumens, intra-and/or intercellular vacuoles whose surfaces were positive for aPKC. Our findings resembled those induced by SiRNA cdc42 knockdown in Caco-2 glands, 13 although in our study, Caco-2 ShPTEN glands were formed from large-sized epithelial cells consistent with PTEN cell size regulation. 57, 58 Cdc42 has a central role in coordination of Caco-2 epithelial morphogenesis. 13 SiRNA knockdown of cdc42 disrupts mitotic spindle orientation, leading to inappropriate positioning of apical membranes and secretion-driven development of multiple abnormal lumens or vacuoles. 13 Conversely, transfection of CA cdc42 reverses the multilumen phenotype of cdc42-deficiency. 4 In this study, we show that Caco-2 ShPTEN cells have low cdc42 activity that can be rescued by wt or CA cdc42 transfection. Furthermore, transfection of Caco-2 ShPTEN cells with wt cdc42 but not EV or DN cdc42 also rescued 3D gland morphogenesis, restoring a single central lumen. As PTEN recruitment of cdc42 to the apical membrane is central to 3D morphogenesis, 1 our data indicate that PTEN could have a role in juxtapositioning of cdc42 with Tuba and ITSN2, to promote cdc42 activation, spindle orientation and aPKC activation. 4 In accord with a previous report, 13 we found that modulation of cdc42 activity did not affect aPKC and E-cadherin localization in apical and basolateral cellular domains.
To assess the effects of PI3K-Akt-targeted treatment on 3D morphogenesis, we treated Caco-2 and Caco-2 ShPTEN cultures initially with EGF or wortmannin. Because of concerns about cell survival effects of PI3-Akt modulating treatment, 59 we applied treatment both at day 1 and after 10 days of culture. This treatment affected epithelial cell size within glands, but did not affect the single or multilumen phenotypes of Caco-2 and Caco-2 ShPTEN glands. Wortmannin has a relatively short half-life in cell cultures 60 that could influence the effectiveness of PI3K/Akt blockade. To address this concern, we repeated morphogenesis experiments using PI-103, a longer acting potent inhibitor of class I phosphatidylinositide 3-kinase. 61 Addition of PI-103 every 48 h effectively suppresses PI3K signaling in cell cultures. 61 In this study we found that PI-103-treated glands were significantly smaller and fewer than control, in line with suppression of the growthpromoting effects of the PI3K/Akt pathway. 32 However, we found that PI-103 did not rescue the abnormal multilumen phenotype of Caco-2 ShPTEN glands.
In our Caco-2 ShPTEN model, PTEN suppression was incomplete and thus potentially amenable to drug treatment. In this study, the PPARg ligand rosiglitazone enhanced PTEN expression and cdc42 activation in Caco-2 and Caco-2 ShPTEN cells, although effects were greater in the former. Rosiglitazone treatment also rescued Caco-2 ShPTEN glandular morphogenesis, restoring a single central lumen in 60% glands. While the PTEN level induced in Caco-2 ShPTEN cells by rosiglitazone remained lower than in VO-treated Caco-2 cells, subtle variations in PTEN level can have important biological consequences in PTEN-deficiency states. 62 For example, low-level PTEN can rescue defective fetal tissue morphogenesis and embryonic lethality as effectively as normal expression levels. 63 To explore the PPARg-dependence of rosiglitazone effects in our model system, cells were cotreated with the PPARg antagonist GW9662. 26 This step effectively blocked rosiglitazone-mediated activation of cdc42 and rescue of Caco-2 ShPTEN glandular morphogenesis. Taken together, our findings are compatible with rosiglitazone promotion of PTEN expression and enhanced PTEN-cdc42-mediated 3D morphogenesis. While we cannot exclude PTEN-independent effects, rosiglitazone merits further investigation as a targeted therapy for glandular dysmorphogenesis in cancer states.
MATERIALS AND METHODS
Reagents and antibodies
All laboratory chemicals including EGF, IGF, wortmannin and LY294002 were purchased from Sigma-Aldrich (Dorset, UK), unless otherwise stated. PI-103 was a generous gift from Dr James Murray, CCRCB, Belfast. Rosiglitazone and GW9662 were purchased from Cambridge Bioscience (Cambridge, UK). Genejuice transfection reagent was purchased from Novagen (Gibbstown, NJ, USA). The antibodies used in this study were rabbit anti-PTEN, -pAkt (Thr308), -Total Akt, -p-GSK3b (Ser9), GSK3b (Cell Signaling Technology, New England Biolabs, Hitchin, Herts, UK), -aPKCz (Abcam); and mouse anti-p-Akt (Ser473), -HA and -GFP (Cell Signaling Technology), -cdc42, -E-cadherin (BD), -GAPDH (Abcam, Cambridge, MA, USA), -Vav2 (Abcam), -ITSN2 (Abcam), -Tuba (a generous gift from Dr Pietro De Camilli, Yale). These primary antibodies were used where appropriate in conjunction with Li-Cor IRDye 680 (anti-rabbit) and IRDye800 (anti-mouse) secondary antibodies, for use with the Li-Cor Infra-Red imaging systems (Li-Cor Biosciences, Lincoln, NE, USA) in western blots or with Alexa Fluor 568 (anti-rabbit) and Alexa Fluor 488 (anti-mouse; Molecular probes, Invitrogen, Carlsbad, CA, USA) and/or anti-mouse CY5 (Jackson Immunoresearch, Newmarket, Suffolk, UK) for fluorescence microscopy. Sepharose 4B beads were purchased from GE Healthcare (Bucks, UK). Plasmids, pcDNA3EGFP-cdc42-WT (no. 12599), pcDNA3EGFP-cdc42 Q61L (CA; no. 12600), pcDNA3EGFP-cdc42 T17N (DN; no.12601) pMKO.1 puro PTEN short hairpin RNA (no. 10669) and pMKO.1 puro EV (no. 8452) were obtained from Addgene Inc., Cambridge, MA, USA. Dharmacon SmartPool PTEN siRNA oligonucleotides and non-targeting control siRNAs were purchased from Fisher Scientific (Dublin, Ireland).
Cell culture PTEN
þ / þ HCT116 and PTEN À / À HCT116 colorectal epithelial cells were a generous gift from Dr Tod Waldman, Georgetown, 27 and were cultured in McCoys 5A media supplemented with 10% fetal calf serum, 1 mM Lglutamine and 1 mM sodium pyruvate and Caco-2 (American Type Culture Collection, Manassas, VA, USA) and Caco-2 ShPTEN cells were cultured in MEM-supplemented 10% fetal calf serum, 1 mM non-essential amino acids and 1 mM L-glutamine at 37 1C in 5% CO 2 .
For glands, Caco-2, Caco-2 ShPTEN cells and subclones stably transfected with EV-EGFP, wt cdc42 or DN cdc42 were cultured embedded in a 'Matrigel' (BD Biosciences, Oxford, UK) matrix, similar to that previously described 13 with modifications. In brief, 6 Â 10 4 trypsinized cells were mixed with HEPES (20 mM), and 'Matrigel' (40%) in a final volume of 100 ml, which was plated into each well of an eight-well chamber slide, allowed to solidify for 30 min at 37 1C and subsequently overlayed with 400 ml of media/well. Glands were cultured for intervals up to 14 days as previously described, 13 but without cholera toxin because of possible concerns about effects on GTPase activity. 64 In treatment studies, PI3K activators EGF (20 ng/ml), IGF (20 ng/ml) or inhibitors wortmannin (2 nM), LY294002 (5 mmol/l) or PI-103 (1.0 mM) were used. Rosiglitazone or GW9662 were used at concentrations of 10 mM each. As the generation of glands by the above method was relatively inefficient, signaling assays were conducted in Caco-2 and Caco-2 ShPTEN cell monolayers.
Cell transfection
Mammalian plasmid transfections were carried out using Genejuice transfection reagent. Cells were plated at 2 Â 10 5 cells/35 mm or at 1 Â 10 6 /90-mm dish 24 h before transfection, then transfected with 500 ng DNA/2 Â 10 5 cells for all constructs. Transfections were carried out according to the manufacturer's protocols. Cells were incubated with DNA-Genejuice complexes for 48 h, before lysis and probing as described in Protein extraction and Western blotting or antibiotic selection for stable transfections. Stable transfection of Caco-2 cells with the previously validated PTEN short hairpin RNA [pMKO.1 ShPTEN or pMKO.1 EV control] 28 was carried out as previously described, 28 with replication-defective retroviruses generated using the Phoenix retroviral expression system (Orbigen, San Diego, CA, USA). Briefly, Caco-2 cells were transfected with viral supernatant on three occasions, then incubated in 1 mg/ml puromycin for selection of ShPTEN-positive subclones. Colonies surviving puromycin selection were subcultured to 60-70% confluence, lysed and probed for PTEN against GAPDH loading control. Clones deficient in PTEN expression were further characterized in terms of AKT signaling and cdc42 activation. Five PTEN-deficient clones were pooled to generate the Caco-2 ShPTEN cell line (Supplementary Figure S1) . Caco-2 ShPTEN cells stably transfected with pEGFP EV, -wt cdc42 and DN-cdc42 constructs were selected in 500 mg/ml G418.
GST PAK cdc42-GTP pulldown Cells were grown on 90-mm dishes, then lysed in buffer comprising 50 mM Tris-HCl (pH 7.5), 1% Triton X-100,100 mM NaCl, 10 mM MgCl 2 , 5% glycerol, 1 mM Na 3 VO 4 and protease inhibitor cocktail (Roche, Indianapolis, IN, USA) and centrifuged at 12 500 g for 10 min. p21 activated kinase binds specifically to active cdc42 and Rac. The GTP-bound form of cdc42 was assayed by adding GST-p21 activated kinase fusion protein coupled with gluthathione sepharose 4B beads to 1 mg of cell lysate. Beads were collected after 1 h by centrifugation, washed three times and resuspended in Laemmli buffer with 1 mM dithiothreitol. Cdc42 activity was then assayed by western blotting, as outlined below. Experiments were repeated in triplicate.
Cell fractionation
Cells were removed from culture dishes in detergent-free lysis buffer (50 mmol/l HEPES, pH 7.4) containing 50 mmol/l NaCl, 1 mmol/l MgCl 2 , 2 mmol/l EDTA and 1 mmol/l Na 3 VO 4 and protease inhibitors and sonicated (3 times 10 s each round). The cell lysate was then centrifuged at 13 000 g for 15 min and the supernatant retained as the cytosolic fraction. The pellets were resuspended in the same buffer, with 1% Triton X-100 and 0.1% SDS added and incubated for 1 h at 4 1C. Membrane fractions were then obtained by centrifugation at 13 000 g for 15 min and the insoluble pellets discarded.
Protein extraction and western blotting
Proteins were resolved using gel electrophoresis, followed by blotting onto nitrocellulose membranes. Membranes were probed using antibodies as indicated in the text.
Immunofluorescence microscopy Embedded glands were fixed in 2% paraformaldehyde for 20 min and processed for immunofluorescence, as previously described for MCF10A glands, 65 with the following modifications. Glands were incubated without the F(ab) 2 fragment for secondary antibody blocking and during immunolabeling with secondary antibodies. DNA was stained and chamber slides mounted using Vectashield mounting medium containing 4'-6-diamidino-2-phenylindol (Vector Scientific, Belfast, NI, USA). Sequential scan images were taken the midsection of glands at room temperature using a Leica SP5 confocal microscope on a HCX PL APO lambda blue 63 Â 1.40 oil immersion objective at Â 1 or Â 2 zoom, as indicated in the figure legends. Images were collected and scale bars added using LAS AF confocal software (Leica Microsystems, Buffalo Grove, IL, USA). In stably transfected Caco-2 glands, four-color confocal microscopy was used when the fluorescent emission spectrum used for E-cadherin (secondary antibody label of Alexa Fluor 488) overlapped with EGFP/tag fluorescence. The secondary label for E-cadherin was changed to Cy5 antibody conjugate under these circumstances.
Image processing and statistical analysis
Fluorescence microscopy images were processed using Leica Fw4000 Imaging software and cropped using Adobe photoshop (CS2). Confocal images were processed, merged and mean area quantified using LAS AF Leica Imaging Software. Data analysis was carried out by one-or two-way analysis of variance using PASW statistics 18 and graphs drawn using Graphpad Prism 5.0. Descriptive statistics were expressed as the mean ± s.e.m.
Online supplement
The online supplement shows characterization of Caco-2 ShPTEN cell line (Supplementary Figure S1) , effects of PTEN siRNA transfection on Cdc42 activity in MDA-MB 235S and A-549 cells (Supplementary Figure S2a) , expression and subcellular localization of 'morphogenic' GEFs Tuba and ITSN2 after VO, EGF or wortmannin (Wtm) treatment (Supplementary Figure S2b) . Videos ( Supplementary Figures S3a and b) show temporal confocal Z stacks of single Caco-2 or Caco-2 ShPTENglands. Supplementary Figure S4 shows effects of cell type and PI3K modulating treatment (EGF/Wortmannin) on cell size within glands (Supplementary Figure S4a) , while Supplementary Figure  S4b shows the effects of PI-103 treatment on size of Caco-2 and Caco-2 ShPTEN glands. Supplementary Figure S5a shows the rosiglitazone doseresponse assay against PTEN expression in Caco-2 and Caco-2 ShPTEN cells. Supplementary Figure S5b shows the effects of rosiglitazone treatment of Caco-2 and Caco-2 ShPTEN gland size. Supplementary Methods for SiRNA knockdown of PTEN are also included.
ABBREVIATIONS aPKC, atypical protein kinase C; CA, constitutively active; cdc42, Cell division cycle 42; DN, dominant negative; EGF, epidermal growth factor; EV, empty vector; GEFs, Guanine nucleotide exchange factors; IGF, insulin-like growth factor; PI3K, Phosphatidylinositol 3-kinase; PtdIns, Phosphatidylinositol; PTEN, phosphatase and tensin homolog deleted on chromosome ten; Ser, serine; ShRNA, Short hairpin RNA; siRNA, small interfering RNA; Thr, threonine; wt, wild type.
